Avricore Health Makes the Grade on 2023 TSX Venture 50

VANCOUVER, British Columbia, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "AVCR") has been honoured by being named as one of the 2023 Venture 50, the TSX Venture Exchange's list of top performing companies.

"To make the Venture 50 feels great and the whole team is excited to keep delivering on our promise to build the world's largest rapid-testing network in pharmacy," said Hector Bremner, CEO of Avricore Health. "Thank you to all our partners and supporters for helping us make this dream of success become a reality!"

Avricore was selected out of over 1700 businesses currently listed on the TSX Venture Exchange for its stellar growth in market capitalization, share price appreciation and trading volume. Driving these results is the scale up and expansion of HealthTab, the Company's point-of-care testing platform, which is on track to becoming the world's largest, most reliable network in community pharmacies.

The Company's current plans are expected to see HealthTab in hundreds of new locations and even new countries, which is expected to drive significant increases in revenues. This means last year's successes will continue to be the trend.

To hear more about this exciting story, visit www.avricore.com and see our TSX Venture 50 video here.

HealthTabtm Market Fast Facts

• Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source)
• Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source)
• Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
• Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source)
• There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.
  

About HealthTabtm

HealthTabtm is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTabtm has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTabtm network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTabtm, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Contact:

Avricore Health Inc.                                        
Hector Bremner, CEO 604-773-8943         
[email protected]                                         
www.avricorehealth.com                                 

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTabtm platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.